ADMA Biologics reported second quarter 2026 revenue of $124.4 million, up 2% year-over-year but slightly missing analyst estimates of $125.34 million. The company posted a GAAP basic EPS of $0.17, beating the consensus estimate of $0.16.

Key Highlights

  • ASCENIV revenue grew 24% year-over-year to $102.9 million, continuing its strong performance but falling short of the 28% growth analysts had projected.
  • The growth in ASCENIV was largely offset by a 49% year-over-year decline in BIVIGAM revenue, which came in at $19.4 million.
  • ADMA reiterated its full-year 2026 financial guidance, which includes total revenue expected between $530 million and $560 million.
  • The company repurchased approximately 7.1 million shares of common stock during the quarter.